1,1-dimethylethyl (2R)-2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate | 934665-54-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1-dimethylethyl (2R)-2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate
• 英文别名: tert-butyl (2R)-2-(3-hydroxy-1-phenylmethoxycarbonylazetidin-3-yl)piperidine-1-carboxylate
• CAS: 934665-54-0
• 化学式: C₂₁H₃₀N₂O₅
• 分子量: 390.48
• InChiKey: QBIMDSMNAAFYPK-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  79.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl (2R)-2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 1,1-dimethylethyl (2R)-2-(3-hydroxyazetidin-3-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  WO2008/76415

  摘要：

  公开号：
• 作为产物：
  描述：

  2-[3-羟基-1-[(苯基甲氧基)羰基]-3-氮杂啶]-1-哌啶羧酸 1,1-二甲基乙酯 在 4-二甲氨基吡啶 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 生成 1,1-dimethylethyl (2R)-2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

  摘要：

  The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types. Mutations associated with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK. Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer. Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metabolism and safety profile versus PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (1). XL518 exhibits robust in vitro and in vivo in preclinical models with sustained duration of action and is currently in early stage clinical trials. potency and efficacy in preclinical models with sustained duration of action and is currently in early stage clinical trials.

  DOI：

  10.1021/ml300049d

文献信息

• Methods of using MEK inhibitors
  申请人：Lamb Peter

  公开号：US20080166359A1

  公开（公告）日：2008-07-10

  The present invention provides methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

  本发明提供了一种通过给予I式化合物或其药学上可接受的盐或溶剂与其他癌症治疗相结合的方法来治疗癌症的方法。
• Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases
  申请人：Aay Naing

  公开号：US20100249096A1

  公开（公告）日：2010-09-30

  Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

  本发明公开了式(I)的化合物及其药学上可接受的盐和溶剂化物。这些化合物是MEK抑制剂，可用于治疗增生性疾病，如癌症。本发明还公开了含有这些化合物的制药组合物，以及使用本发明的化合物和组合物治疗癌症的方法。
• Azetidines as MEK inhibitors for the treatment of proliferative diseases
  申请人：Exelixis, Inc.

  公开号：US07803839B2

  公开（公告）日：2010-09-28

  Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

  本发明涉及式(I)化合物及其药学上可接受的盐和溶剂化物。这些化合物是MEK抑制剂，可用于治疗增殖性疾病，如癌症。本发明还涉及含有这些化合物的制药组合物，以及使用本发明的化合物和组合物治疗癌症的方法。
• MEK Inhibitors And Methods Of Their Use
  申请人：Exelixis, Inc.

  公开号：US20150141399A1

  公开（公告）日：2015-05-21

  Disclosed are compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

  本发明公开了I式化合物及其药学上可接受的盐和溶剂化物。这些化合物是MEK抑制剂，可用于治疗增殖性疾病，如癌症。本发明还公开了含有这些化合物的制药组合物，以及使用本发明的化合物和组合物治疗癌症的方法。
• WO2008/76415
  申请人：——

  公开号：——

  公开（公告）日：——